Pembrolizumab for Metastatic NSCLC Patients Expressing PD-L1 Who Have Their Own PDX
Status:
Recruiting
Trial end date:
2021-06-30
Target enrollment:
Participant gender:
Summary
This is a single center, open-label, single arm study in patients with metastatic non-small
cell lung cancer (NSCLC) expressing PD-L1 after failure of platinum-based combination
chemotherapy.
Patients will be treated with Pembrolizumab according to the dosage and administration in
Product Information of Keytruda in Korea (2mg/kg) until it is changed to 200mg flat dose.
The patient should have their-own patient-derived xenograft (PDX) before enrollment of the
study. The PDX will be used to set up their humanized CD34 PDX (Hu-CD34 PDX).